Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03037957 · ClinicalTrials.gov registry record
A Multi-Site Clinical Evaluation of the ARIES Group A Strep Assay in Symptomatic Patients
A clinical trial, sponsored by Luminex Corporation.
- Completed
- Registry status
- 704
- Enrollment target
NCT03037957: Completed study, sponsored by Luminex Corporation.
NCT03037957 is a clinical trial that has completed, run by Luminex Corporation. The registered enrollment target is 704 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03037957 has completed, sponsored by Luminex Corporation.
- COMPLETED
- Registry status
- 704 participants
- Enrollment target
Study Summary
A multi-center evaluation to assess the diagnostic sensitivity and specificity of the ARIES Group A Strep Assay will be established through a method comparison using prospectively collected, de-identified, clinical samples collected during the enrollment period.
Interventions
- DEVICE ARIES Group A Strep Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 704 participants |
| Start Date | 2017-01-09 |
| Est. Completion | 2017-06-02 |
What the finished NCT03037957 record still lists
NCT03037957 is an observational study that tracks outcomes without assigning an intervention. The registered 704 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which ARIES Group A Strep Assay is the first listed.
NCT03037957 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03037957 about?
NCT03037957 is a clinical study titled "A Multi-Site Clinical Evaluation of the ARIES Group A Strep Assay in Symptomatic Patients". A multi-center evaluation to assess the diagnostic sensitivity and specificity of the ARIES Group A Strep Assay will be established through a method comparison using prospectively collected, de-identified, clinical samples collected during the enrollment period.
What is the current status of trial NCT03037957?
This trial is currently completed. The enrollment target is 704 participants. The study started on 2017-01-09. Estimated completion is 2017-06-02.
What interventions are being tested in trial NCT03037957?
The interventions under investigation include: ARIES Group A Strep Assay (DEVICE).
Who is sponsoring clinical trial NCT03037957?
This trial is sponsored by Luminex Corporation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05796687 · 704 participants · NA
Evaluation of My Future Self, an New Teen Pregnancy Prevention Group Intervention for Youth in Non-traditional Settings
- NCT06350734 · 704 participants
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
- NCT06480383 · 705 participants · Phase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
- NCT07067463 · 705 participants · Phase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI